These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 2180471)

  • 1. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
    Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
    Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Gyllenhammar H; Johansson B; Juliusson G; Järnmark M
    Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
    J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
    Bladé J; San Miguel JF; Fontanillas M; Esteve J; Maldonado J; Alcalá A; Brunet S; García-Conde J; Besalduch J; Moro MJ; Fernández-Calvo J; Conde E; Font L; Gardella S; Carnero M; Carbonell F; Martí JM; Hernández-Martín J; Ortega F; Besses C; Ribera JM; Trujillo J; Escudero ML; Rozman C; Estapé J; Montserrat E
    Hematol J; 2001; 2(4):272-8. PubMed ID: 11920260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
    J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
    Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
    Bladé J; San Miguel J; Alcalá A; Maldonado J; García-Conde J; Moro MJ; Sanz Sanz MA; Alonso C; Zubizarreta A; Besses C
    Blut; 1990 Jun; 60(6):319-22. PubMed ID: 2198075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG; Dixon DO; Carter S; Stephens R; Rivkin S; Bonnet J; Salmon SE; Dabich L; Files JC; Costanzi JJ
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
    Bladé J; San Miguel JF; Fontanillas M; Alcalá A; Maldonado J; García-Conde J; Conde E; Conzález-Brito G; Moro MJ; Escudero ML; Trujillo J; Pascual A; Rozman C; Estapé J; Montserrat E
    J Clin Oncol; 1996 Jul; 14(7):2167-73. PubMed ID: 8683251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
    Bladé J; Muñoz M; Fontanillas M; San Miguel J; Alcalá A; Maldonado J; Besses C; Moro MJ; García-Conde J; Rozman C; Montserrat E; Estapé J
    Age Ageing; 1996 Sep; 25(5):357-61. PubMed ID: 8921139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
    Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
    Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current results of a multicenter trial in multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Deicher H; Boll J; Essers U; Gamm H; Glück S; Görg K; Gramatzki M
    Onkologie; 1986 Jun; 9(3):168-9. PubMed ID: 3528964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; von Broen IM; Fischer JT; Gramatzki M
    Onkologie; 1990 Dec; 13(6):458-60. PubMed ID: 2092283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; Fett W; Fischer JT; Göbel B
    Eur J Cancer; 1995; 31A(2):146-51. PubMed ID: 7718318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
    J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
    Sakalová A; Bock PR; Dedík L; Hanisch J; Schiess W; Gazová S; Chabronová I; Holomanova D; Mistrík M; Hrubisko M
    Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S38-44. PubMed ID: 11561871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.